研究證實人類乳突病毒疫苗可提供近二十年的保護力
Study confirms HPV vaccine provides protection for nearly two decades
公共衛生領域出現重大突破：最新數據證實，人類乳突病毒（HPV）疫苗能提供長達近二十年的強健保護。
A major breakthrough in public health has arrived: new data confirms that the HPV vaccine provides robust protection for nearly two decades.
廣泛的研究追蹤已接種疫苗者長達二十年，結果顯示其免疫力並未減弱。
Extensive research, monitoring vaccinated individuals for up to 20 years, shows no decline in immunity.
這證實了該疫苗在接種後極長一段時間內，對預防子宮頸癌及其他HPV相關癌症皆具高度效力。
This confirms the vaccine is highly effective at preventing cervical and other HPV-related cancers long after it is administered.
在青少年前期接種該疫苗，可降低80%至90%的子宮頸癌罹患風險，使其成為防癌的強大工具。
When given to pre-adolescents, the vaccine can reduce the risk of cervical cancer by 80–90%, making it a powerful tool for cancer prevention.
瑞典和蘇格蘭等國的實證數據顯示，大規模免疫接種能產生群體免疫效應，顯著降低病毒傳播。
Real-world data from nations like Sweden and Scotland shows that mass immunization creates herd immunity, significantly reducing virus transmission.
除子宮頸癌外，該疫苗還能保護免受喉癌及其他生殖器官癌症的威脅。
Beyond cervical cancer, the vaccine protects against various other cancers of the throat and reproductive areas.
二十年的監測證實了其高度安全性，專家認為這是推動全球消滅子宮頸癌的綠燈。
With two decades of monitoring confirming its high safety profile, experts view this as a green light to push for global elimination of cervical cancer.
儘管科學共識已達成，下一步的挑戰在於確保全球民眾皆能公平地獲取這項救命的醫療介入。
While the science is settled, the next challenge is ensuring equitable access to this life-saving intervention worldwide.
透過及早接種，我們能在癌症發生前阻斷它，這證明了主動式醫療是我們對抗疾病的最強防線。
By vaccinating early, we can stop cancer before it starts, proving that proactive healthcare is our strongest defense against disease.
